Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Sponsor: Iambic Therapeutics, Inc
Summary
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Official title: A Phase 1/1b Study of IAM1363 in Patients With Advanced Cancers Harboring HER2 Alterations
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
243
Start Date
2024-03-25
Completion Date
2028-03
Last Updated
2026-02-03
Healthy Volunteers
No
Conditions
Interventions
IAM1363
Oral, immediate release capsules of IAM1363
Locations (45)
UCSD Moores Cancer Center
La Jolla, California, United States
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
University of Colorado Cancer Center
Aurora, Colorado, United States
University of Miami
Miami, Florida, United States
Comprehensive Hematology Oncology
St. Petersburg, Florida, United States
University of Chicago
Chicago, Illinois, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Henry Ford Cancer Institute
Detroit, Michigan, United States
START - Midwest Cancer Research Center
Grand Rapids, Michigan, United States
Saint Luke's Cancer Institute
Kansas City, Missouri, United States
Washington University School of Medicine
St Louis, Missouri, United States
RUTGERS Cancer Institute
New Brunswick, New Jersey, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Duke Cancer Institute
Durham, North Carolina, United States
University Hospital Cleveland Medical Center
Cleveland, Ohio, United States
Cleveland Clinic
Cleveland, Ohio, United States
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
Providence Cancer Institute
Portland, Oregon, United States
SCRI Oncology Partners
Nashville, Tennessee, United States
Vanderbilt Ingram Cancer Center
Nashville, Tennessee, United States
NEXT Oncology - Austin
Austin, Texas, United States
NEXT Oncology - Dallas
Dallas, Texas, United States
Mary Crowley Cancer Research
Dallas, Texas, United States
MD Anderson Cancer Center - University of Texas
Houston, Texas, United States
START Mountain Region
West Valley City, Utah, United States
NEXT Oncology - Virginia Cancer Specialists
Fairfax, Virginia, United States
Fred Hutchinson Cancer Center
Seattle, Washington, United States
Centre Georges François Leclerc
Dijon, France
Institut de Cancerologie de l'Ouest
Saint-Herblain, France
Institut Universitaire du Cancer de Toulouse (IUCT) Oncopole Institut Claudius Regaud "
Toulouse, France
The START center Dublin
Dublin, Dublin, Ireland
Cork University Hospital, Wilton
Cork, Ireland
St. Vincent's University Hospital
Dublin, Ireland
Azienda Ospedaliero Universitaria Careggi - Largo Giovanni Alessandro Brambilla 3
Florence, Italy
Netherlands Cancer Institute-Antoni van Leeuwenhoek
Amsterdam, Netherlands
Seoul National University Hospital
Seoul, South Korea
Severance Hospital - Yonsei Cancer Center
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Hospital Universitario Vall dHebron
Barcelona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
START Madrid CIOCC, Hospital Universitario HM Sanchinarro
Madrid, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Hospital Clinico Universitario de Valencia (INCLIVA)
Valencia, Spain